709 related articles for article (PubMed ID: 26073897)
1. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
[TBL] [Abstract][Full Text] [Related]
3. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.
Sun YX; Schneider A; Jung Y; Wang J; Dai J; Wang J; Cook K; Osman NI; Koh-Paige AJ; Shim H; Pienta KJ; Keller ET; McCauley LK; Taichman RS
J Bone Miner Res; 2005 Feb; 20(2):318-29. PubMed ID: 15647826
[TBL] [Abstract][Full Text] [Related]
4. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
6. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
8. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
9. Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach.
Xing Y; Liu M; Du Y; Qu F; Li Y; Zhang Q; Xiao Y; Zhao J; Zeng F; Xiao C
Cancer Biol Ther; 2008 Nov; 7(11):1839-48. PubMed ID: 18836306
[TBL] [Abstract][Full Text] [Related]
10. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
11. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
12. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of Chanling Gao on the proliferation and liver metastasis of transplanted colorectal cancer in nude mice.
Yang B; Pan CS; Li Q; Yang Z; Long FX; Fan JY; Wang CS; Han JY; Tang DX
PLoS One; 2019; 14(2):e0201504. PubMed ID: 30789971
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.
Wuchter P; Leinweber C; Saffrich R; Hanke M; Eckstein V; Ho AD; Grunze M; Rosenhahn A
Cell Tissue Res; 2014 Feb; 355(2):315-26. PubMed ID: 24337688
[TBL] [Abstract][Full Text] [Related]
15. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?
Hirbe AC; Morgan EA; Weilbaecher KN
Curr Pharm Des; 2010; 16(11):1284-90. PubMed ID: 20166978
[TBL] [Abstract][Full Text] [Related]
16. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma.
Zhao BC; Wang ZJ; Mao WZ; Ma HC; Han JG; Zhao B; Xu HM
World J Gastroenterol; 2011 May; 17(19):2389-96. PubMed ID: 21633638
[TBL] [Abstract][Full Text] [Related]
17. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
18. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor.
Lin G; Yang R; Banie L; Wang G; Ning H; Li LC; Lue TF; Lin CS
Prostate; 2010 Jul; 70(10):1066-73. PubMed ID: 20232361
[TBL] [Abstract][Full Text] [Related]
19. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.
Taichman RS; Cooper C; Keller ET; Pienta KJ; Taichman NS; McCauley LK
Cancer Res; 2002 Mar; 62(6):1832-7. PubMed ID: 11912162
[TBL] [Abstract][Full Text] [Related]
20. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
